Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reached a new 52-week low on Tuesday after The Goldman Sachs Group downgraded the stock from a buy rating to a neutral rating. The Goldman Sachs Group now has a $25.00 price target on the stock. Ultragenyx Pharmaceutical traded as low as $18.37 and last traded at $19.0540, with a volume of 1005279 shares traded. The stock had previously closed at $20.27.

Several other research firms also recently commented on RARE. JPMorgan Chase & Co. reduced their price target on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research note on Thursday, March 12th. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Robert W. Baird reduced their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Jefferies Financial Group lowered their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Finally, Leerink Partners dropped their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Fifteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.47.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total value of $36,624.00. Following the transaction, the chief financial officer directly owned 85,034 shares of the company’s stock, valued at approximately $1,904,761.60. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 54,404 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer owned 658,994 shares in the company, valued at approximately $15,025,063.20. This trade represents a 7.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 104,958 shares of company stock valued at $2,394,858 over the last three months. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. Assetmark Inc. lifted its stake in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank lifted its position in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $39,000. Elevation Point Wealth Partners LLC acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth about $55,000. Finally, Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

The stock has a 50 day simple moving average of $22.70 and a two-hundred day simple moving average of $28.39. The firm has a market cap of $1.85 billion, a PE ratio of -3.28 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.39) EPS. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.